Chiesi Farmaceutici S.p.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chiesi Farmaceutici S.p.A.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cornerstone Therapeutics (Cardiokine, Inc.
- Critical Therapeutics, Inc.
- EKR Therapeutics Inc.)
- Torrex Chiesi Pharma
- Zymenex Holding A/S
- Atopix Therapeutics Limited